Press Releases Tenaya Therapeutics, Inc.

Equities

TNYA

US87990A1060

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
4.66 ^USD	+9.65%		+10.95%	+43.83%

May. 16	Canaccord Genuity Adjusts Tenaya Therapeutics Price Target to $16 From $18, Maintains Buy Rating	MT
Mar. 20	Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	May. 14	AQ
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting	May. 02	AQ
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 18	AQ
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine	Mar. 18	AQ
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences	Feb. 27	AQ
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications	Feb. 26	AQ
Tenaya Therapeutics Announces Pricing of Underwritten Offering	Feb. 08	AQ
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	AQ
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference	Nov. 21	AQ
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 08	AQ
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy	23-10-26	AQ
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting	23-10-09	AQ
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy	23-10-05	AQ
Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration	23-10-02	AQ
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences	23-09-21	AQ
Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference	23-08-31	AQ
Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update	23-08-09	AQ
Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference	23-08-02	AQ
Heart Failure Pipeline, Clinical Trials, and Key Companies\|Companies - Zensun (Shanghai) Sci & Tech, Windtree Therapeutics, TreeFrog Therapeutics	23-06-16	AQ
TENAYA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	23-06-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Tenaya Therapeutics, Inc.

Equities

TNYA

US87990A1060

Press Releases

Filters